-
Product Insights
Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) - Drugs In Development, 2024
Empower your strategies with our Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer) – Drugs In Development, 2024 report and make more profitable business decisions. Non-Muscle-Invasive Bladder Cancer (NMIBC), also referred to as superficial bladder cancer, is a type of bladder cancer that is confined to the innermost lining of the bladder. Unlike muscle-invasive bladder cancer, which penetrates the muscle layer of the bladder wall, NMIBC stays within the lining and does not invade deeper layers or surrounding tissues. NMIBC...
-
Product Insights
Chronic Myelomonocytic Leukemia (CMML) - Drugs In Development, 2024
Empower your strategies with our Chronic Myelomonocytic Leukemia (CMML) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic Myelomonocytic Leukemia (CMML) is a type of rare blood cancer that combines features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). It primarily affects the bone marrow and blood cells, resulting in the overproduction of abnormal monocytes (a type of white blood cell) and other blood cells. CMML is characterized by an increased number of monocytes in the...
-
Product Insights
Lung Adenocarcinoma - Drugs In Development, 2024
Empower your strategies with our Lung Adenocarcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Lung adenocarcinoma is the most common type of non-small cell lung cancer (NSCLC), accounting for a significant portion of lung cancer cases. It typically arises in the outer regions of the lungs and tends to develop in the smaller airways, known as bronchioles. Adenocarcinoma is characterized by cancerous cells that form glandular structures resembling the normal cells found lining the lungs. It...
-
Product Insights
Merkel Cell Carcinoma - Drugs In Development, 2024
Empower your strategies with our Merkel Cell Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, ultraviolet exposure, and immune suppression. Symptoms include painless nodules on the skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and...
-
Product Insights
Natural Killer Cell Lymphomas - Drugs In Development, 2024
Empower your strategies with our Natural Killer Cell Lymphomas – Drugs In Development, 2024 report and make more profitable business decisions. Natural killer (NK) cell lymphomas are a rare and aggressive type of lymphoma arising from a subset of white blood cells called natural killer cells, which are part of the body's immune system. These lymphomas can affect various organs and tissues in the body. NK cell lymphomas are categorized into two main types. Extranodal NK/T-cell lymphoma, nasal type (ENKTL) is...
-
Product Insights
Rectal Cancer - Drugs In Development, 2024
Empower your strategies with our Rectal Cancer – Drugs In Development, 2024 report and make more profitable business decisions. Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources, and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as...
-
Product Insights
Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy - Drugs In Development, 2024
Empower your strategies with our Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy – Drugs In Development, 2024 report and make more profitable business decisions. Angioimmunoblastic T-cell lymphoma (AITL), previously known as immunoblastic lymphadenopathy, is a rare and aggressive form of peripheral T-cell lymphoma that originates from mature T cells in the immune system. AITL typically affects individuals in late adulthood and often presents with generalized symptoms including enlarged lymph nodes, fever, night sweats, weight loss, skin rashes, and an increased risk of infections....
-
Product Insights
Metastatic Brain Tumor - Drugs In Development, 2024
Empower your strategies with our Metastatic Brain Tumor – Drugs In Development, 2024 report and make more profitable business decisions. Metastatic brain tumors, also known as secondary brain tumors, occur when cancer cells spread to the brain from a primary cancer elsewhere in the body. These tumors are more common than primary brain tumors, arising from cancers originating in other organs such as the lungs, breast, colon, or skin (melanoma) and then migrating to the brain through the bloodstream or lymphatic...
-
Product Insights
Leiomyosarcoma - Drugs In Development, 2024
Empower your strategies with our Leiomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Leiomyosarcoma is an aggressive soft tissue sarcoma derived from smooth muscle cells typically of uterine, gastrointestinal, or soft tissue origin. Symptoms include a noticeable lump or swelling; pain, if it presses on nerves or muscles; and a blockage in the stomach or intestines or gastrointestinal bleeding if the tumor is located in the abdomen or digestive tract. Predisposing factors include age, chemical exposure,...
-
Product Insights
Rhabdomyosarcoma - Drugs In Development, 2024
Empower your strategies with our Rhabdomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy,...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.